Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1419787rdf:typepubmed:Citationlld:pubmed
pubmed-article:1419787lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C0226896lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C0205531lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C1527415lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C0205177lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C2266987lld:lifeskim
pubmed-article:1419787lifeskim:mentionsumls-concept:C1518062lld:lifeskim
pubmed-article:1419787pubmed:issue1lld:pubmed
pubmed-article:1419787pubmed:dateCreated1992-12-21lld:pubmed
pubmed-article:1419787pubmed:abstractTextSeveral iron chelators, 3-hydroxypyridin-4-ones (CP) and desferrioxamine (DF) were compared for their effect on DNA synthesis, cell viability and expression of cell proliferation markers. Short-term (4 h) exposure of human peripheral blood mononuclear cells to CP or DF inhibited the proliferative response of cells to concanavalin A (Con A). Inhibition by CP and DF showed a dose-dependent effect with CP compounds more active than DF. Increased inhibitory activity of CP over DF was partly due to the lipophilic properties of CP. Pre-saturation of CP and DF with exogenous ferric ion either diminished or prevented the inhibitory effect. At high chelator concentrations or prolonged (72 h) exposure of the cells to chelators, inhibition occurred but poor cell viability was observed. In contrast to their inhibition of DNA synthesis, these iron chelators showed little effect on protein synthesis and the expression of transferrin receptors and interleukin-2 (IL-2) receptors. These findings suggest that both DF and CP compounds exert their effect by chelation of ferric ion with subsequent inhibition of DNA synthesis.lld:pubmed
pubmed-article:1419787pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:languageenglld:pubmed
pubmed-article:1419787pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:citationSubsetIMlld:pubmed
pubmed-article:1419787pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1419787pubmed:statusMEDLINElld:pubmed
pubmed-article:1419787pubmed:monthSeplld:pubmed
pubmed-article:1419787pubmed:issn0007-1048lld:pubmed
pubmed-article:1419787pubmed:authorpubmed-author:HiderR CRClld:pubmed
pubmed-article:1419787pubmed:authorpubmed-author:WebsterH KHKlld:pubmed
pubmed-article:1419787pubmed:authorpubmed-author:Pattanapanyas...lld:pubmed
pubmed-article:1419787pubmed:authorpubmed-author:TongtawePPlld:pubmed
pubmed-article:1419787pubmed:authorpubmed-author:KongcharoenPPlld:pubmed
pubmed-article:1419787pubmed:issnTypePrintlld:pubmed
pubmed-article:1419787pubmed:volume82lld:pubmed
pubmed-article:1419787pubmed:ownerNLMlld:pubmed
pubmed-article:1419787pubmed:authorsCompleteYlld:pubmed
pubmed-article:1419787pubmed:pagination13-9lld:pubmed
pubmed-article:1419787pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:meshHeadingpubmed-meshheading:1419787-...lld:pubmed
pubmed-article:1419787pubmed:year1992lld:pubmed
pubmed-article:1419787pubmed:articleTitleEffect of orally active hydroxypyridinone iron chelators on human lymphocyte function.lld:pubmed
pubmed-article:1419787pubmed:affiliationThalassaemia Centre, Faculty of Graduate Studies, Siriraj Hospital, Mahidol University, Bangkok, Thailand.lld:pubmed
pubmed-article:1419787pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1419787pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:1419787pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:1419787pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed